NXTC Stock — NextCure Inc.: Cash, EV, Pipeline

Share price

$6.12

Market cap

$28.0M

Cash

$20.1M

Enterprise value

$7.9M

Balance sheet

Cash	$20.1M
Debt	$0.0M
Net cash	$20.1M
Enterprise value	$7.9M
Basic shares	4.1M shares
Fully diluted shares	5.7M shares
Fully diluted market cap	$35.1M
Cash per share	$4.90

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NXTC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	LNCB74	Phase 1	Ovarian Cancer; Breast Cancer; Endometrial Cancer	—
Mar 14 - Apr 25	SIM0505 for injection	Phase 1	Advanced Solid Tumors; Platinum Resistant Ovarian Cancer; Fallopian Tube Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SIM0505

Phase 1 · Terminated Modality: antibody-drug conjugate (ADC)

Aliases SCR-9359

Target CDH6

Partnerships Simcere Zaiming Pharmaceutical Co., Ltd.: license agreement (Jun 13, 2025); exclusive worldwide license (excluding China, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialize SIM0505; $17M total ($12M upfront + $5M payable on financing event or Dec 31, 2025); Phase 1 initiation milestone of $1.5M became payable Oct 2025

Indications

Multiple cancers (Phase 1)

Status note On Jul 14, 2026, informed all U.S. clinical trial sites to stop screening, consenting, enrolling and delivering first doses to new patients; no expansion to Europe/Canada; working with sites to cease treatment of patients currently on study and transition them to alternative therapies. Decision not based on any negative safety or efficacy finding or dispute with Zaiming.

LNCB74

Phase 1 · Active Modality: antibody-drug conjugate (ADC)

Target B7-H4

Partnerships LigaChem Biosciences, Inc.: Research Collaboration and Co-Development Agreement (Nov 2022); costs incurred prior to Jul 1, 2026 shared 50-50; subsequent to Jun 30, 2026, LigaChem elected to continue the program as Sole Developing Party and will pay NextCure developmental, regulatory and commercial milestones plus single-digit royalties on future net sales

Indications

Multiple cancers (high B7-H4 expression; including breast, ovarian and endometrial) (Phase 1)

Status note FDA accepted IND Dec 2024; first patient dosed Jan 2025; protocol amendment cleared Nov 2025 for higher dose escalation cohorts. NextCure discontinued further investment in the co-development program in connection with the Avere merger; LigaChem continues the program as Sole Developing Party.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LNCB74
Lead indication	Ovarian Cancer
Lead phase	Phase 1
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06774963	Phase 1	Recruiting	Sponsor	NXTC	—	Ovarian Cancer; Breast Cancer; Endometrial Cancer	—
NCT06792552	Phase 1	Recruiting	Sponsor	NXTC	—	Advanced Solid Tumors; Platinum Resistant Ovarian Cancer; Fallopian Tube Cancer	—
NCT04699123	Phase 2	Active, not recruiting	Collaborator	Yale University	MRK	Advanced Non-small Cell Lung Cancer	—
NCT06941857	Phase 2	Recruiting	Collaborator	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	—	Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for NextCure, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	288,303	+50,000	0.08%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NXTC — NextCure Inc.